The first generation of this new blood screen test system holds the potential to greatly enhance the emergency room triage process of determining which, of the millions of patients in the US annually entering emergency rooms with abdominal pain, are high risk candidates for appendicitis and require more significant diagnostic work-ups such as CT scanning. In addition to improving the overall diagnostic process surrounding this common condition in the ER, this new blood-based test could save potentially billions of dollars in unnecessary CT scans and appendicitis surgeries in the US alone.
With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting an overwhelming need for more accurate, faster, and more economical assessment of the appendicitis condition. They are anticipated to be the first and only such tests available. The company has initiated the FDA application process and anticipates a fall 2007 initial regulatory filing. The FDA approval process for diagnostic tests is typically much shorter than for drugs, and if successfully completed and approved, management's estimates suggest a worldwide, several hundred million dollar annual market potential. The patent portfolio for the AppyScore/AppyScreen appendicitis diagnostic technologies has also been significantly expanded over recent months.
About the NASDAQ
NASDAQ is the largest U.S. equities exchange operated by The Nasdaq
Stock Market, Inc. (Nasdaq: NDAQ). With approximately 3,200 companies, it
lists more companies and, on average, trades more shares per day than any
other U.S. market. It is home to companie
|SOURCE AspenBio Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved